

2020 Second Extraordinary Session

SENATE RESOLUTION NO. 28

BY SENATOR FESI

HEALTH CARE. Requests the Louisiana Department of Health to report on the use and results of hydroxychloroquine for treating Medicaid recipients relative to COVID-19.

1 A RESOLUTION

2 To urge and request the Louisiana Department of Health to report on the use and results of
3 hydroxychloroquine for treating Medicaid recipients relative to COVID-19.

4 WHEREAS, hydroxychloroquine, also known as hydroxychloroquine sulfate, was
5 approved for medical use in the United States in 1955; and

6 WHEREAS, hydroxychloroquine is used to treat rheumatoid arthritis and lupus, and
7 can be used to prevent malaria; and

8 WHEREAS, hydroxychloroquine has been proposed as a treatment for COVID-19
9 and has been the focus of several randomized, double-blind, placebo-controlled trials across
10 the United States and parts of Canada; and

11 WHEREAS, according to the Louisiana Department of Health, as of October 19,
12 2020, there have been 2,594,376 COVID-19 tests administered; 175,982 confirmed COVID-
13 19 diagnoses; and 5,566 confirmed COVID-19 deaths in Louisiana; and

14 WHEREAS, more than 1.8 million Louisianians are enrolled in the state Medicaid
15 program; and

16 WHEREAS, Medicaid recipients' services covered and outcomes achieved are
17 reliable and readily available data sets that can be used to determine the use and results of
18 hydroxychloroquine.

1 THEREFORE, BE IT RESOLVED that the Senate of the Legislature of Louisiana
2 does hereby request the Louisiana Department of Health to report on the use and results of
3 hydroxychloroquine for treating Medicaid recipients relative to COVID-19.

4 BE IT FURTHER RESOLVED that the department shall report the following
5 information for the control period of March 2020 through October 2020:

6 (1) The number of Medicaid recipients who were taking hydroxychloroquine for
7 rheumatoid arthritis, lupus, or to prevent malaria during the control period and tested
8 positive for COVID-19.

9 (a) Of those recipients who tested positive for COVID-19, how many were
10 hospitalized and what was the duration of the hospitalization.

11 (b) Of those recipients who tested positive for COVID-19, how many deaths occurred
12 whether hospitalized or not.

13 (2) The number of Medicaid recipients who were not taking hydroxychloroquine for
14 rheumatoid arthritis or lupus, or to prevent malaria during the control period, tested positive
15 for COVID-19, and were treated with hydroxychloroquine as a COVID-19 post-exposure
16 prophylaxis.

17 (a) Of those recipients treated with hydroxychloroquine as a COVID-19
18 post-exposure prophylaxis, how many were hospitalized and what was the duration of the
19 hospitalization.

20 (b) Of those recipients treated with hydroxychloroquine as a COVID-19
21 post-exposure prophylaxis, how many deaths occurred whether hospitalized or not.

22 BE IT FURTHER RESOLVED that the department shall submit a data report to the
23 Senate no later than December 1, 2020.

24 BE IT FURTHER RESOLVED that a copy of this Resolution be transmitted to the
25 secretary of the Louisiana Department of Health.

The original instrument and the following digest, which constitutes no part
of the legislative instrument, were prepared by Christine Arbo Peck.

DIGEST

SR 28 Original

2020 Second Extraordinary Session

Fesi

Requests the Louisiana Department of Health to report on the use and results of
hydroxychloroquine for treating Medicaid recipients relative to COVID-19.